$TRAW News

Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks

Traws Pharma Announces Advancement Of Its Novel Proprietary Broad-Spectrum Combination Anti-Viral Agent With Potential Utility Against Hantavirus, Ebola and Lassa

HC Wainwright & Co. Reiterates Buy on Traws Pharma, Maintains $8 Price Target

Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results

Traws Pharma Q1 EPS $(0.53) Beats $(0.56) Estimate

Chuck Schumer Blasts Trump, Elon Musk For Firing CDC And Port Health Workers As Hantavirus Scare Grips The World

Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak

Traws Pharma Announces Plans To Advance Potential Clinical Candidates For The Treatment Of Hantavirus Infection

Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Traws Pharma, Inc. Q4 2025 Earnings Call Summary

Traws Pharma Inc (TRAW) Q4 2025 Earnings Call Highlights: A Turnaround Year with Significant ...

Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript

TRAWS PHARMA INC (NASDAQ:TRAW) Reports 2025 Earnings Beat Amid Dilutive $60M PIPE Financing and FDA Hold

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

Traws Pharma Q4 EPS $(0.71) Misses $(0.69) Estimate

Traws Pharma Announces Up to $60 Million Private Placement Financing

Traws Pharma Prices $10M PIPE At $1.673/Share For 5.98M Shares, Issues Warrants For Up To 29.9M Shares With $50M Additional Upside Potential

hVIVO, Connecting Excellence, ACG Metals, Kodal Minerals, Ariana Resources, Sunda Energy

Traws Pharma shares are trading lower. The company announced completion of the clinical analysis of its Phase 2 study of ratutrelvir versus PAXLOVID in COVID-19 patients.

Traws Pharma shares are trading lower. The company announced completion of the clinical analysis of its Phase 2 study of ratutrelvir versus PAXLOVID in COVID-19 patients.